Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$3.72 USD
+0.04 (0.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKBA 3.72 +0.04(0.95%)
Will AKBA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Other News for AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AKBA Stock News
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business ...
Core CPI In Focus With JPMorgan, Goldman, Netflix Set To Report Earnings
Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office